bpc-157 adverse effects case report human FDA's Review Of Peptides Signals A Growing Public Health Challenge The Hidden Risks of BPC‑157:

Patients who used Zepbound for 36 weeks lost an average of 21%, but then, when switched to a placebo, after 1 year, they had regained 14% of their weight back

It is observation of suspicious improvements that could indicate undisclosed medication use

Its main mechanism of action revolves around actin sequestration

Cochrane Database Syst Rev 2:CD006271 Petrovic I, Dobric I, Drvis P et al (2006) An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157

There are no reports of significant hormonal disruption, no blood sugar effects, and no serious adverse events attributable to the peptide